60 Degrees Pharmaceuticals Inc

This proposal asks shareholders to approve an increase of 800,000 shares to the company’s 2022 Equity Incentive Plan to create a larger reserve for equity awards. Management frames the request as necessary to attract and retain employees, directors and consultants and to preserve flexibility for future grants, noting the plan’s existing automatic annual increases and current reserved amount as context. Board approval would increase the plan’s total authorized reserve substantially, which creates a larger potential pool for stock options, restricted stock, RSUs and other awards—immediately raising dilution risk if all shares were issued but providing the company with greater compensation flexibility. From a governance perspective, shareholder approval is standard for material share increases and helps ensure compliance with listing rules and perceived market norms; the company also attaches the formal amendment language as Annex A. Analysts will weigh the dilution trade-off against the potential benefits of improved retention, especially in a competitive biotech labor market where equity is a key incentive. Important considerations include the current outstanding share count, existing option overhang, and the company’s cadence of grants—information partially disclosed in the proxy—but absent explicit grant pacing or reuse limits, shareholders should anticipate management discretion over allocation. The proposal also contains typical administrator powers (e.g., to determine exercise prices, vesting, amendments), which concentrates substantive plan control with the Board/Compensation Committee. While the Board recommends FOR and emphasizes recruitment and retention needs, sophisticated investors will evaluate whether the increase is sized and conditioned appropriately relative to corporate capitalization, historical grant practices, and alignment of long-term shareholder value creation. Approving the amendment preserves optionality for the company, but shareholders should monitor future disclosures about award levels, dilution outcomes, and any refresh mechanics to ensure alignment with shareholder interests.

This management proposal asks shareholders to authorize the Board to effect a reverse split of the company’s common stock at a ratio selectable by the Board between 1-for-5 and 1-for-10 within one year of approval. Management’s stated rationale is primarily to raise the per-share trading price to satisfy Nasdaq continued listing standards and thereby preserve access to public markets, which is operationally critical for capital raising and liquidity. The proposal also cites potential secondary benefits such as improved marketability to institutional and broker-dealer clients, reduced susceptibility to market manipulation common in low-priced securities, and the incidental increase in available authorized but unissued shares for future corporate uses. From a governance standpoint, granting the Board discretion over timing and exact ratio is common but concentrates significant unilateral authority—investors should consider the precise ratio range and the one-year implementation window. The tradeoffs for shareholders include the risk that the market capitalization could decline if post-split market pricing does not scale proportionally, and potential liquidity reduction due to fewer outstanding shares and higher odd-lot incidence. The company intends to eliminate fractional shares by issuing whole shares in lieu of fractions, which may slightly benefit small holders but can also increase share issuance marginally. Anti-takeover concerns are noted by the company because a reverse split increases the number of authorized but unissued shares, which could be used defensively, so shareholders should weigh that governance implication. Overall, the proposal is a defensive and compliance-driven tool to protect listing status and market perceptions, and the appropriate investor assessment balances the near-term listing benefit against dilution, liquidity and takeover-related considerations.

This proposal seeks shareholder approval for a pre-defined success-fee program that would pay management a tiered fee—5% of deal proceeds for transactions between $40M and $100M, and 6% for transactions above $100M—payable in cash, equity, or a combination as the Board determines. Management presents the fee as an alignment mechanism to incentivize executives to maximize transaction value in the event of a change of control, strategic transaction, or sale of Arakoda; the Board also emphasizes transparency by submitting the arrangement to shareholders even though it reserves the legal authority to implement cash-based arrangements without shareholder approval. From a governance lens the explicit percentages and deal-value bands increase clarity for investors, but the Board’s retained discretion over allocation among individual managers and the form of payment (cash vs. equity) raises potential conflict-of-interest concerns and may dilute shareholder returns if paid in equity. The voluntary submission indicates management sensitivity to optics, yet the company’s statement that it could still implement a cash-only plan if not approved weakens the practical force of shareholder consent. Financially, the fee represents a meaningful cost on the transaction proceeds—especially in the $40–100M band where 5% materially reduces net proceeds available to shareholders—and could affect deal negotiations or counterparties’ perceptions. Investors should evaluate whether the fee structure is consistent with market norms for similarly sized biotech transactions and whether governance safeguards (e.g., allocation formulas, clawbacks, independence of advisors) are adequate. The Board’s unanimous recommendation suggests internal support, but independent shareholders may demand post-approval transparency on actual allocations and payments. In sum, the mechanism aligns incentives but introduces potential dilution and agency concerns that should be managed through clear disclosure and limits on how the fee is allocated and paid.

This routine procedural proposal asks shareholders to authorize the Board to adjourn the meeting, if necessary, to solicit additional proxies so that the Company can obtain sufficient votes to approve specified substantive proposals (director elections, the equity plan amendment, and the reverse-split amendment). Such adjournment authority is a common governance mechanism that allows management to continue outreach and proxy solicitation without reconvening at a later scheduled annual meeting, thereby preserving operational flexibility. For shareholders, the core issue is whether management should be empowered to extend the solicitation period; opponents sometimes view adjournments as delaying tactics that could pressure investors, but supporters argue it is an efficient way to ensure an adequately representative vote. The proposal requires a majority of votes cast to approve and treats abstentions and broker non-votes as not cast for this purpose, which can make achieving approval numerically easier than proposals that count abstentions as negative votes. If approved, the Board can use standard solicitation tools during the adjournment to address outstanding concerns and gather additional support, but shareholders should monitor any extended solicitation for new disclosures or changes in the facts underpinning the original proposals. In contested contexts, adjournments can materially extend timelines and costs; here, the company indicates the intent to use it only if needed to pass specific governance and capital-structure measures. Overall, the proposal is a standard housekeeping mechanism giving the company pragmatic flexibility to complete its proxy process, with relatively limited substantive impact beyond potential delays and additional solicitation expense.